There is a 15-minute delay in the prices. To check out the live prices, log in to your Ventura account or open one today.
| Orders | Qty | Bid |
|---|---|---|
| Ask | Qty | Orders |
|---|---|---|
Annual Revenue,rose 3.7%, in the last year to ₹13,458.26 Cr. Its sector's average revenue growth for the last fiscal year was 10.63%.Annual Net Profit,rose 20.59% in the last year to ₹2,165.48 Cr. Its sector's average net profit growth for the last fiscal year was 36.65%.Price to Earning Ratio,is 29.67, lower than its sector PE ratio of 40.1.Alkem Laboratories Limited is an Indian pharmaceutical company established in 1973, with 50+ years of growth and a rank as the 5th largest pharma company in India by market share. The company focuses on branded and trade generics, biosimilars, and medical devices, and also offers Bio Contract Development and Manufacturing (BioCDMO) services through Enzene Biosciences. Its revenue mix is predominantly from India, contributing ~70% in recent years, alongside fast-growing international operations with 30%+ contribution. The company has a meaningful presence across 10+ countries and reports an international revenue contribution split of 22% from the US and ~10% from RoW markets.
Alkem operates 19 manufacturing facilities, including 5 that are USFDA-approved, and 4 R&D centres spanning sites such as Baddi, Sikkim, Daman, Taloja and Pune in India, plus facilities in California and an expected New Jersey site slated to be operational in late FY25. Its platforms cover tablets, injectables, APIs, biosimilars and more than 10 technology platforms.
Key milestones include the first plant at Taloja, Mumbai (1978); first R&D facility at Taloja (2003); India’s first anti-infective drug to cross Rs 100 crore annual domestic sales (Taxim, 2006); first US ANDA filing (2007) and approval (2009); acquisitions in the US and Australia (2010–2012); IPO (2015); US annual sales crossing US$ 200 Million (2018); revenue crossing US$ 1 billion (2019); a new biologic/biosimilar facility in Pune (2020); Enzene’s first India launch (2021); and the launch of Eyecare (Ophthalmology) division and the 50-year milestone (2023).
Alkem develops and markets pharmaceutical formulations (branded and trade generics), biosimilars and medical devices, and provides BioCDMO services via Enzene. It operates across key therapy areas and technology platforms, supported by extensive manufacturing and R&D infrastructure.
The company has a predominantly India-focused business (~70% of revenue), with international operations contributing 30%+; within this, 22% comes from the US and ~10% from RoW. It has a meaningful presence across 10+ countries.
As of December 31, 2024, Alkem had filed 179 ANDAs and 2 NDAs, and received 154 approvals (including 15 tentative) and 2 NDA approvals; in Q3 FY25, it received two USFDA approvals. Enzene’s US BioCDMO facility is expected to go live in late FY25.
